首页> 外文期刊>Cancer causes and control: CCC >An institutional strategy to increase minority recruitment to therapeutic trials
【24h】

An institutional strategy to increase minority recruitment to therapeutic trials

机译:一种增加少数族裔参与治疗性试验的体制策略

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual. Methods: We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators. Results: Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 % in 2005 to 14.0 % in 2010. The "rolling average" minority cancer incidence at the institution during this timeframe was 17.5 %. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346-552, 60 % increase, p < 0.05) compared to a 52 % increase for Caucasians. Conclusions: Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.
机译:目的:参与治疗性临床试验很少反映出患者群体的种族和种族组成。为了实现美国国立卫生研究院的目标,需要增加参与度的策略。我们提出了少数群体临床试验应计制的制度增强框架。方法:我们在四个层次上实施了结构性改革,以诱导和维持少数族裔应计入临床试验:(1)领导支持; (2)中心范围内的政策变化; (3)基础设施过程控制,数据分析和报告; (4)与临床研究者进行随访。协议审查和监控委员会审查研究并监控应计项目,而消除癌症差异计划则致力于按比例应计项目,通过数据跟踪,Web工具以及对调查人员的反馈来支持系统。结果:自2005年实施以来,治疗试验中应占的少数族裔比例从2005年的12.0%增加到2010年的14.0%。在此期间,该机构的“滚动平均”少数族裔癌症发病率是17.5%。除了治疗性试验的应计率,我们注意到,从2005年到2010年,参加所有试验(治疗性和非治疗性)的少数族裔人数显着增加(346-552,增加60%,p <0.05),而2005年增加了52%高加索人。结论:实施一个系统以帮助研究人员计划和建立应计目标,同时要求该组成部分作为年度协议审查和应计监测的一部分,可提供可在其他癌症中心复制的成功策略,该方法可能会扩展其他临床和转化研究中心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号